Best of all, Kimberly-Clark realized it needs to consolidate, which is why it’s acquiring Kenvue, J&J’s old consumer health business. The Kenvue Catalyst and Defensive MoatThe acquisition of Kenvue Inc. (NYSE:KVUE), the consumer health business spun off from Johnson & Johnson (NYSE:JNJ), gives Kimberly-Clark control over everyday staples including Tylenol, Neutrogena, Listerine, and Band-Aids. Plus, the Kenvue acquisition gives it a credible path towards faster growth, higher margins, and a much broader health and wellness platform. Upon transaction closing (scheduled for H2 2026), the new KMB stock issued to Kenvue shareholders will be used directly to cover the short positions. READ NEXT: Jim Cramer Draws the Line on NVIDIA in China: Why National Security Comes First and Jim Cramer Defends His Dell Stance as Investors Complain About Missing Out.